AzTrials
AzTrials

Antenatal Congenital MalformationsDPNI-ExomeNCT05182242

Comparison of the Non-invasive Approach and Fetal Exome Sequencing in Prenatal Diagnosis When Fetal Ultrasound Signs Are Discovered

A study testing Collection of clinical data, Collection of samples and Questionnaires in people with Antenatal Congenital Malformations, run by Centre Hospitalier Universitaire Dijon at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The discovery of congenital malformations and/or non-specific signs by ultrasound (5% of pregnancies) represents a real medical challenge. Their prognosis is variable depending on the underlying etiology, ranging from acquired fetopathies to rare genetic diseases. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Antenatal Congenital Malformations
What is being tested?
Collection of clinical data, Collection of samples and Questionnaires
Could I receive a placebo?
No, everyone receives an active treatment
How many people
75 participants
Where
1 siteFrance
Study dates
8 Mar 2022to 14 Mar 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Pregnant women with prenatal discovery of fetal malformations on ultrasound that may justify the performance of a fetal exome sequencing (e.g., multiple malformations and/or severe brain malformation, microphthalmia, bone damage, severe cardiac damage, etc.) who will have or are having an invasive prenatal sample for array CGA diagnosis and for which the results of the ES could change the outcome of the pregnancy
  • Sufficient quantity of fetal sample (amniotic fluid or fetal blood or fetal DNA) for the collection of an additional sample for the ES
  • Ability to collect blood samples from the pregnant woman and the biological father of the fetus (peripheral blood)
  • Pregnant woman and father of the fetus aged ≥18 years
  • Pregnant woman and father of the fetus able to comprehend the situation
  • Person who has provided written consent

Who cannot join

  • - Refusal of the pregnant woman or biological father to participate in the study
  • Pregnancy before 11 weeks of amenorrhea or after 34 weeks of amenorrhea (to limit the risk of reporting results after birth)
  • Pregnant women and/or biological fathers who are not affiliated to the national health insurance systel
  • Pregnant women and/or biological fathers under some type of legal protection (guardianship, trusteeship, etc.)
  • Pregnant women and/or biological fathers who are unable to express their consent
  • Organizational study:
Show all 9Show fewer
  • In addition to the inclusion \& exclusion criteria of the main study:
  • Pregnant woman and/or biological father of fetus who provided oral consent to be interviewed
  • Professionals (obstetrician, midwife, geneticist, biologist) willing to be interviewed or participate in a focus group

Trial locations and contacts

1 site in 1 country.

France1 site
  • CHU Dijon Bourgogne

    Dijon

Other trials in France

About this study

The discovery of congenital malformations and/or non-specific signs by ultrasound (5% of pregnancies) represents a real medical challenge. Their prognosis is variable depending on the underlying etiology, ranging from acquired fetopathies to rare genetic diseases. In France, the diagnostic approach is currently based on imaging examinations (ultrasound, brain MRI, 3D bone scans, etc.) and/or biological examinations, generally on invasive sampling (trophoblast biopsy, amniocentesis or fetal blood puncture) with infectious (CMV, toxoplasmosis, parvovirus B19, etc.), metabolic (enzymes in the bloodstream, etc.), and genetic (standard karyotype, FISH, array CGH and targeted gene sequencing) investigations. The yield of this strategy is about 30%, leaving 70% of couples without a possible prognosis.

Over the last decade, medical genetics has undergone a technological revolution with the development of high-throughput DNA sequencing (HTS) allowing the analysis of targeted genes (panel) or the exome (ES). International studies published on the use of ES in prenatal diagnosis (PND) have become more common, with variable inclusion criteria, resulting in diagnostic rates between 15 and 36%, higher than those of array CGH (8-15%). In France, FHU TRANSLAD coordinates the national pilot study AnDDI-PRENATOME, which has made it possible to remove the technological barriers for PND ES and to obtain a diagnostic yield of 39% in 33 days on average.

Read more

In parallel, the recent development of NIPD (Non-invasive prenatal screening) on free fetal DNA circulating in maternal blood has made it possible to propose a non-invasive strategy. However, this technique is currently used in prenatal care only in a few indications: determination of the fetal sex, search for aneuploidies, analysis of the fetal rhesus status or, more rarely, the targeted diagnosis of monogenic diseases. The team in Strasbourg has recently conducted a pilot study using an NIPD-panel in couples with a history of neomutation in a gene responsible for intellectual disability, which has demonstrated the feasibility of capturing and then sequencing a panel of 500 genes on free fetal DNA circulating in maternal blood.

As high-depth exome sequencing from small amounts of DNA is now affordable and feasible, the investigators wish to compare invasive and non-invasive approaches for the discovery of fetal malformations on ultrasound: a trio exome analysis will be performed in parallel to circulating fetal DNA and fetal DNA extracted after an invasive puncture in order to compare the diagnostic performance of these two approaches.

The investigators propose a pilot study in order to prepare an organizational evaluation including an evaluation of the stakes for coordination and interactions between professionals, the relevance of the system (acceptability, expectations, satisfaction of couples and professionals...), its effectiveness and efficiency. The aim of this pilot project will be to observe the organizational impact on the Plurldisciplinary Centers for Prenatal Disagnostics and the genetic laboratories, and to refine the indicators necessary for monitoring the system; it will also involve conducting exploratory interviews with professionals and couples in order to prepare the qualitative study that will subsequently make it possible to evaluate the relevance of the organization.

Being tested
Collection of clinical data, Collection of samples, Questionnaires, Parent interviews, Professional interview and focus groups

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Collection of clinical dataOther

    family history, clinical data, ultrasound and all other data necessary for the study on a e-CRF (CleanWEB), allowing the collection of the family tree, and if necessary photographic elements.

  • Collection of samplesBiological

    Collected during fetal and blood sampling performed as part of care for ACPA:

    • 4 Streck tubes maximum for the pregnant woman for NIPD-Exome, collected prior to invasive fetal sampling
    • 1 additional vial of fetal sample (amniotic fluid or fetal blood) and 1 EDTA tube for each of the two parents
  • QuestionnairesOther

    within the framework of the pilot study (optional): questionnaires (about 20 minutes) for the evaluation of the experience, perceptions, impact of the analyses on the decision, satisfaction and concerns regarding exome sequencing (ES) and its results, opinion on certain types of results currently not reported, anxiety, possible psychological difficulties

  • Parent interviewsOther

    as part of the pilot study (optional): interview (about 1 hour) with a sociologist to explore perceptions of ES and the impact of the results, expectations about certain types of results that are not currently available, emotional situation, position regarding the continuation of the pregnancy

  • Professional interview and focus groupsOther

    Interview (approximately 45 minutes) to understand how the decision is formed Focus groups to help clarify whether the Variants of Unknown Significance (VUSs) should potentially be returned to the clinicians, or even the patient via the clinician

Study groups in NCT05182242
Study groupRoleWhat they receive
PatientsExperimentalPregnant women with sonographic signs
Receives: Other: Collection of clinical data; Biological: Collection of samples; Other: Questionnaires; Other: Parent interviews
Health professionalsOtherbiologists, geneticists, obstetricians, midwives of the Pluridisciplinary Centers of Prenatal Diagnosis and genetic services
Receives: Other: Professional interview and focus groups

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. number of etiological diagnosis common to the 2 analysis techniques : NIPD exomes and trio fetal ES

    Measured: At baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jan 2022
  2. Study start8 Mar 2022
  3. Primary completion14 Mar 2024
  4. Study completion14 Mar 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
75 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05182242
Sponsor's protocol ID
NAMBOT PHRCI 2020
Acronym
DPNI-Exome
Status last verified
Feb 2025
First submitted
16 Dec 2021
Last updated
20 Feb 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Racine C, Garde A, Martz O, Safraou H, Eluard V, Rousseau T, Marle N, Harizay FT, Martin L, Maraval J, Bruel AL, Philippe C, Thauvin-Robinet C, Faivre L. First Prenatal Case of Genotypically and Phenotypically Overlapping Double Molecular Diagnosis of Van den Ende-Gupta and 22q11.2 Deletion Syndromes. Mol Genet Genomic Med. 2025 Apr;13(4):e70096. doi: 10.1002/mgg3.70096.

    PubMed 40237608

Questions about this trial

What is this clinical trial studying?

A study testing Collection of clinical data, Collection of samples and Questionnaires in people with Antenatal Congenital Malformations, run by Centre Hospitalier Universitaire Dijon at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

number of etiological diagnosis common to the 2 analysis techniques : NIPD exomes and trio fetal ES (time frame: At baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05182242, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in